Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01303796 is registered in ClinicalTrials.gov with Cyclacel Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01303796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01303796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 1, 2011
Completion date
July 31, 2017
Enrollment
482 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia